Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ward

Showing results (221-230 of 249) with videos related to

Pageof 25
Sort By:
Reproductive Biology and Endocrinology : RB&E|March 10, 2010
Alterations in the steroid hormone receptor co-chaperone FKBPL are associated with male infertility: a case-control studyOlaf Sunnotel, Laszlo Hiripi, Kevin Lagan, et al.
Toxins|March 4, 2020
Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal MelanomasAdriana Tomoko Nishiya, Marcia Kazumi Nagamine, Ivone Izabel Mackowiak da Fonseca, et al.
Nature Medicine|March 5, 2026
The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trialCatherine J Mummery, Arthur J Mayorga, Adam Simmons, et al.
Biorxiv : the Preprint Server for Biology|October 1, 2025
Generation of <i>C9orf72</i> repeat knock-in iPSC lines for modelling ALS and FTDRachel Coneys, Alexander J Cammack, Remya R Nair, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 23, 2023
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series AnalysisKuan Peng, Joseph E Blais, Nicole L Pratt, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohortPierre N Tariot, Francisco Lopera, Jessica B Langbaum, et al.
Biorxiv : the Preprint Server for Biology|February 5, 2024
TDP-43 loss induces extensive cryptic polyadenylation in ALS/FTDSam Bryce-Smith, Anna-Leigh Brown, Puja R Mehta, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
TDP43 autoregulation gives rise to shortened isoforms that are tightly controlled by both transcriptional and post-translational mechanismsMegan M Dykstra, Kaitlin Weskamp, Nicolás B Gómez, et al.
Organic Process Research & Development|January 31, 2022
Development of a Robust Manufacturing Route for Molnupiravir, an Antiviral for the Treatment of COVID-19Patrick S Fier, Yingju Xu, Marc Poirier, et al.
Cell Reports|January 10, 2025
TDP43 autoregulation gives rise to dominant negative isoforms that are tightly controlled by transcriptional and post-translational mechanismsMegan M Dykstra, Kaitlin Weskamp, Nicolás B Gómez, et al.
Pageof 25

Showing results (221-230 of 249) with videos related to

Sort By:
Pageof 25
Reproductive Biology and Endocrinology : RB&E|March 10, 2010
Alterations in the steroid hormone receptor co-chaperone FKBPL are associated with male infertility: a case-control studyOlaf Sunnotel, Laszlo Hiripi, Kevin Lagan, et al.
Toxins|March 4, 2020
Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal MelanomasAdriana Tomoko Nishiya, Marcia Kazumi Nagamine, Ivone Izabel Mackowiak da Fonseca, et al.
Nature Medicine|March 5, 2026
The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trialCatherine J Mummery, Arthur J Mayorga, Adam Simmons, et al.
Biorxiv : the Preprint Server for Biology|October 1, 2025
Generation of <i>C9orf72</i> repeat knock-in iPSC lines for modelling ALS and FTDRachel Coneys, Alexander J Cammack, Remya R Nair, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 23, 2023
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series AnalysisKuan Peng, Joseph E Blais, Nicole L Pratt, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohortPierre N Tariot, Francisco Lopera, Jessica B Langbaum, et al.
Biorxiv : the Preprint Server for Biology|February 5, 2024
TDP-43 loss induces extensive cryptic polyadenylation in ALS/FTDSam Bryce-Smith, Anna-Leigh Brown, Puja R Mehta, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
TDP43 autoregulation gives rise to shortened isoforms that are tightly controlled by both transcriptional and post-translational mechanismsMegan M Dykstra, Kaitlin Weskamp, Nicolás B Gómez, et al.
Organic Process Research & Development|January 31, 2022
Development of a Robust Manufacturing Route for Molnupiravir, an Antiviral for the Treatment of COVID-19Patrick S Fier, Yingju Xu, Marc Poirier, et al.
Cell Reports|January 10, 2025
TDP43 autoregulation gives rise to dominant negative isoforms that are tightly controlled by transcriptional and post-translational mechanismsMegan M Dykstra, Kaitlin Weskamp, Nicolás B Gómez, et al.
Pageof 25